Company profile
vTv Therapeutics Inc.
NASDAQ: VTVT · Healthcare · Biotechnology
#1161 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
57CFH 69DQ 59GM 22SS 52
v0.1 · 65/100 weight · provisional
↑ Piotroski F, Altman-Z · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$36.8M
Rev growth YoY (TTM)
+216600.0%
Net income (FY)
-$27.0M
Employees
26
as of 2026-08-18
Market cap
$81.0M
as of 2026-08-18
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$27.0M-$27.0M2025
Operating income-$32.8M-$32.8M2025
Total assets$89.9M$89.9M2025
Liabilities$25.5M$25.5M2025
Equity$64.4M$64.4M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2024
By product
Reportable100%
By geography
Not disclosed.
The read
What is vTv Therapeutics Inc.’s revenue?
vTv Therapeutics Inc. booked $0 in FY2025 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Revium Recovery Inc.——HST Global, Inc.——MAIA Biotechnology, Inc.34DAnnovis Bio, Inc.33DPliant Therapeutics, Inc.48DXBiotech Inc.47DNeighbors
Guilford →Key facts
CEOPaul J. Sekhri
SectorHealthcare
IndustryBiotechnology
HeadquartersHigh Point, NC
ExchangeNASDAQ: VTVT
Employees26
IPO date2015-07-30
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.